ASX:ACWBiotechs
Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen
Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway.
Concerned by Actinogen Medical's cash runway...